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Three key points: 
(1) A physician-implemented medication screening intervention based on the STOPP/START criteria 
demonstrated positive outcomes in terms of reduction of adverse drug reactions in older hospitalised patients. 
 
(2) The physician-implemented intervention is not likely to be cost-effective compared with usual care, 
unless the healthcare provider is willing to pay a large amount of money to prevent an adverse drug reaction. 
 
(3) Pharmacist and/or computerised clinical decision support systems employed to carry out such 
medication reviews may be a more cost-effective approach than acquiring a physician. 
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Background: A recent randomised controlled trial (RCT) conducted in an Irish University teaching hospital 
that evaluated a physician-implemented medication screening tool, demonstrated positive outcomes in terms of 
reduction of incident adverse drug reactions (ADRs).  
Objective: The present study objective was to evaluate the cost-effectiveness of physicians applying this 
screening tool to older hospitalised patients compared with usual hospital care in the context of the earlier RCT. 
Method: Cost-effectiveness analysis alongside conventional outcome analysis in a cluster RCT. Patients in the 
intervention arm (n= 360) received a multifactorial intervention consisting of medicines reconciliation, 
communication with patients’ senior medical team and generation of a pharmaceutical care plan in addition to 
usual medical and pharmaceutical care. Control arm patients (n= 372) received usual medical and 
pharmaceutical care only. Incremental cost-effectiveness was examined in terms of costs to the healthcare 
system and an outcome measure of ADRs during inpatient hospital stay. Uncertainty in the analysis was 
explored using a cost-effectiveness acceptability curve (CEAC).  
Results: On average, the intervention arm was more costly but was also more effective. Compared with usual 
care (control), the intervention was associated with a non-statistically significant increase of €877 (95% CI 
−€1,807, €3,561) in mean healthcare cost, and a statistically significant decrease of −0.164 (95% CI −0.257, 
−0.070) in the mean number of ADR events per patient. The associated incremental cost-effectiveness ratio 
(ICER) per ADR averted was €5,358. The probability of the intervention being cost-effective at threshold values 
of €0, €5,000 and €10,000 was 0.236, 0.455 and 0.680 respectively.   
Conclusion: Based on the evidence presented, this physician-led intervention is not likely to be cost-effective 
compared with usual hospital care. More economic analyses of structured medication reviews by other 
healthcare professionals and by computerised clinical decision support software (CDSS) need to be explored to 
inform future healthcare policy decisions in this field.  




















1 Introduction  
Within the 35 member countries of the Organisation for Economic Co-operation and Development (OECD), 
people born today have an average life expectancy of 80.6 years [1]. Given this 10-year increase in life 
expectancy from just 45 years ago, the greatly expanded older person population is one of the most resource-
consuming patient groups interfacing with healthcare systems in all OECD countries [2]. This cohort is often 
exposed to inappropriate prescribing and polypharmacy [3, 4] which can frequently lead to adverse drug 
reactions (ADRs) [5, 6]. The increasing incidence of ADRs within the older population is a growing health 
problem [7]. It is estimated that approximately 2000 bed days are due to an ADR at any one time and where the 
total costs are likely to exceed £171 million annually for ADRs occurring during admission in the UK [8]. This 
cost rises to approximately £1 billion when all ADRs are taken into account [9].  Initiatives which enhance 
medication management in the older people can ameliorate patient outcomes and attenuate unnecessary 
expenditure [10, 11]. Given that an estimated 57% of all ADRs are considered avoidable, it makes sense to 
invest in interventions to prevent ADRs, particularly in older people who are at highest risk [12]. 
Structured and unstructured medication reviews in the hospital environment can be an effective means to 
optimise pharmacotherapy. However, there can be variability in the ways these reviews are implemented. [13]. 
They are generally carried out on an ad hoc basis and can differ depending on which healthcare professional 
performs the review [14]. The published literature has numerous examples of randomised controlled trials 
(RCTs) testing different interventions that have the common overarching aim of improving prescribing in the 
older adult [15-17]. One trial in particular demonstrated a statistically significant reduction in serious ADRs 
[18]. However there are only two published clinical trials that have used potentially inappropriate medication 
(PIM) or potential prescribing omission (PPO) criteria as a structured medication review intervention for the 
purpose of ADR prevention in high-risk hospitalised older adults [19, 20].  
Both of these RCTs have employed the widely used STOPP/START (Screening Tool of Older Persons’ 
Prescriptions / Screening Tool to Alert doctors to Right Treatment) criteria (version 1) [21]. The fundamental 
aim of the STOPP criteria is to minimise medication-related adversity by highlighting and avoiding PIMs. The 
complementary aim of the START criteria is to minimise preventable therapeutic failures by highlighting PPOs 
and encouraging appropriate prescriptions if they are absent for no justified clinical reason [22]. One of these 
cluster RCTs applied a structured pharmacist review of medication (SPRM) which was supported by a 
computerised clinical decision support system (CDSS). It resulted in significant reductions of ADRs [20] and 
proved cost-effective [23].  
The other cluster RCT involved a single time-point intervention in which patients had their medications 
screened according to the STOPP/START criteria by a physician. Instances in which STOPP and START 
“rules” had been contravened were highlighted to the attending medical team with advice to adjust the patients’ 
prescriptions accordingly. This once-off application of STOPP/START criteria alongside usual pharmaceutical 
care resulted in a significant reduction in  incident ADRs compared to similar older patients receiving usual 
pharmaceutical care only [19]. However, before adopting any medication optimisation technology, appraisal of 
its economic and budgetary impact is important. Notwithstanding the significant ADR attenuation that arose 
from the application of the STOPP/START criteria [19], an economic evaluation of this intervention has not yet 
been undertaken. The aim of this study was to conduct a cost-effectiveness analysis of the physician-
implemented structured medication review based on its application in a RCT in an older population that aimed 
to reduce incident hospital-acquired ADRs. This is the first economic evaluation of a physician-led intervention 
that is based on the application of the STOPP/START criteria.   
2 Methods  
2.1 The Prevention of ADRs in Older Hospitalised Patients RCT  
Full details of the particular RCT methods are published elsewhere [19, 24]. In brief, the single-blinded RCT 
was conducted in an 810-bed University teaching hospital in the south of Ireland over a 13-month period 
between May 2011 and May 2012. This trial was cluster-randomised with consultants from each speciality 
represented in each trial arm. Patients were randomised into either intervention or control groups based on the 
consultant with primary responsibility for their care during their hospital stay. The intervention arm consisted of 
360 patients. The control arm included 372 patients. All in this study received usual medical and pharmacist 
inpatient care, which consisted of full medication reconciliation, surveillance of prescription order sheets 
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(independent of medical prescribers) with specific written advice attached to the prescription order sheets. The 
baseline characteristics and trial-related outcomes of the study population are presented (see Table 1). No 
significant differences existed between the groups in terms of age, functional status, cognitive function or 
number of medications at entry to the study [19]. Although there was a statistically significant sex imbalance 
between the groups, it is unlikely that this had a significant influence on the primary outcome results [19, 25]. 
 
 Table 1 Baseline characteristics and trial-related outcomes of study population in the RCT 
Variable  Measure  Intervention (n = 360)  Control (n = 372)  P-value 
Age   Median (IQR)  80 (73-85)  78 (72-84)  0.100 
Male  n (%)  130 (36.1%)  187 (50.3%)  0.001 
Female   n (%)   230 (63.9%)   185 (49.7%)   0.001 
Nursing home 
residents 
n (%)   51 (14.1%) 36 (9.6%) 0.080 
Total number of 
daily drugs 
n 3,147 3,212 0.520 
Distribution of 
drugs 
Median (IQR) 9 (6-11) 8 (6-11) 0.710 
Length of hospital 
stay    
Median (IQR)   8 (4 – 14)  8 (4 – 14)  0.961 
Hospital mortality 
rate  
n (%)  11 (3.1%)  9 (2.4%)  0.535 
Key: IQR – Interquartile range, NS – Non-significant (Type 1 error rate of 0.05 used)  
A research physician applied the STOPP/START intervention to patients’ medication lists within 48 hours of 
admission. The intervention consisted of three elements. The first of these involved the research physician 
applying the STOPP/START criteria once only in each intervention group participant on the basis of the 
diagnoses documented in their case records and the list of prescribed drugs and doses at the time of study 
enrolment. The second element involved the research physician discussing the presence of any STOPP/START-
defined PIMs and/or PPOs with a senior member of the patient’s attending team (i.e. senior residents or in most 
cases, consultants). Thirdly, within 24 hours of applying STOPP/ START criteria, the research physician placed 
a printed report in the participant’s case record, reinforcing the oral recommendations based on the specific 
criteria that applied in each case. The final decision regarding acceptance or rejection of STOPP and START 
criteria recommendations lay with the participant’s attending senior medical staff. All patients aged ≥ 65 years 
admitted under the care of the medical or surgical services through the emergency department were considered 
eligible for inclusion.  However, exclusion criteria were:  (i) aged < 65 years, (ii) admission directly to 
psychiatric services, intensive care unit, palliative care unit, specialist geriatric or clinical pharmacology 
services, (iii) anticipated length of stay (LOS) <48 hours, (iv) elective admission, (v) terminal illness, (vi) 
refusal to participate. 
2.2 Economic Evaluation   
The economic evaluation consisted of a trial-based analysis conducted alongside the cluster RCT. The 
perspective of the Irish public healthcare provider, the Health Service Executive (HSE), was adopted with 
respect to trial-related costs and outcomes. Evidence on resource use and patient health outcomes were collected 
by the research physician during the course of the trial and a retrospective review of patient medical records was 
carried out. The time horizon for ADR evaluation was confined to patient discharge or 10-day follow-up, 
whichever was sooner; this was informed by average LOS for an elderly patient in the Irish hospital system at 
the time [26]. The average LOS for patients aged 65 – 74 years is 7.9 days and is 10.4 days for patients aged 75 
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– 84 years. The study was not designed to measure the medium/long term impact of this intervention and 
discounting of costs or outcomes was not required due to the limited follow-up period. Moreover, 
missing/censored data were not an issue in this evaluation, as follow-up was facilitated by a unique hospital 
number identifier and confined to a single centre over a short time period. Statistical analysis was conducted on 
an intention to treat (ITT) basis, and in accordance with guidelines for conducting economic evaluations 
alongside cluster RCTs [27], which require that both the correlation and clustering of the cost and effect data be 
explicitly considered.  
2.3 Cost Analysis  
Multiple cost components were included in the analysis and are described (see Table 2). Costs are expressed in 
Euros (€) using 2012 prices (unless otherwise stated). The primary component was the cost of employing the 
research physician, who then held the post of specialist registrar (i.e. senior resident) physician in geriatric 
medicine, to implement the required intervention steps. The mid-point of the HSE specialist registrar physician 
pay scale was used and adjusted according to guidelines for conducting economic evaluation in Ireland [28, 29]. 
Salary was adjusted for employers’ insurance cost, pension payments and general overheads. Based on 
experience-based opinion from the primary research team and estimates from the literature [30], it was assumed 
for the analysis that 40 minutes was an appropriate duration to assign for the trained research physician to apply 
the intervention.   
The second component consisted of the associated follow-up time for senior members of patients’ attending 
teams to discuss and decide upon the suggested STOPP/START recommendations. Based on experience-based 
opinion from the primary research team, it was assumed for the analysis that this took seven minutes. The mid-
point on the HSE consultant physician pay scale was used in the cost analysis. The third major component was 
the cost of hospital inpatient stay; this cost was obtained from aggregated national data [31]. In general, micro-
costing estimates for patients are preferable. However, in the context of this piece of research, the 24-hour 
national Irish hospital stay average cost per patient was more pragmatic to use despite patients being admitted 
with a diverse range of primary indications. The fourth component consisted of the specialist registrar’s training 
in the use of STOPP/START criteria. Interactive training courses given by the creators of the STOPP/START 
criteria generally last for approximately four hours and were costed accordingly. 
All resource use was valued using a vector of unit cost data presented in 2012 Euro (€) prices and summed to 
calculate a total cost variable for the statistical analysis given that the trial was completed in 2012. However, at 
the time of manuscript preparation (December 2017), the contemporaneously available healthcare costs (CAHC) 
in the Irish context were re-applied to the intervention steps. These costs are expressed in 2015 Euros (€) prices 
(unless otherwise stated). See Electronic Supplementary Material Table S1 (ESM Table S1). Statistical analysis 
was re-run with the CAHC and original trial effectiveness data (see ESM2). This supplementary analysis was 
undertaken as a point of interest to examine the stability of medical inflation in Ireland during the post financial 
crisis period. 
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2.4 Effectiveness Analysis  
The primary outcome measure of this cluster RCT was the difference in the proportion of participants in the two 
arms experiencing one or more ADRs during index hospitalisation. ADRs were identified by the research 
physician and a blinded second researcher. A comprehensive description of ADR identification and outcomes is 





2.5 Cost-Effectiveness Analysis  
In an economic evaluation, one health technology (treatment/intervention) is considered more cost-effective 
than its comparator if it meets one of the following criteria [32];  
a) Less costly and more effective;  
b) More costly but more effective, with an incremental cost-effectiveness ratio (ICER) which is 
considered acceptable by decision-makers;   
c) Less costly and less effective, but the additional cost per unit of effect of its comparator is not 
considered worth paying by decision-makers.  
In the context of the current study, we conduct a cost effectiveness analysis to identify which of the three 
conditions applies here. Notably, the ICER represents the additional cost per unit effect, which in this case, is 
the additional cost of preventing an additional non-trivial ADR in secondary care. This raises the concern of 
what healthcare policymakers and decision-makers in Ireland would be willing to pay to prevent an ADR. While 
threshold values exist for some generic measures such as quality-adjusted life years (QALYs), no such value per 
ADR prevented currently exists. In this analysis, we present our results in the context of a number of 
hypothetical thresholds, as previously proposed in the literature [23]. Recent work that compares methods for 
estimating direct costs of ADRs may inform a threshold value for ADR prevention in the future [33]. 
Statistical techniques were adopted to account for the effect of both clustering and correlation of cost and effect 
data collected alongside cluster RCTs [34]. The incremental analysis was undertaken using multilevel regression 
models for both the cost and effect data. Both models were estimated to control for treatment arm, age, sex, 
number of medications at admission and consultant (cluster group). The regression for total cost variable was 
estimated using a multilevel mixed-effects linear regression model and the regression for the ADR event 
variable was estimated using a mixed-effects logistic regression model. The estimated treatment arm effects 
represent the incremental costs and incremental effects for the intervention relative to the control. The 95% 
confidence intervals report the statistical significance of these co-efficients based on standard errors estimated 
using the ‘mixed’ command in STATA® version 13 (IBM SPSS Statistics 22; IBM Corporation, Armonk, NY, 
USA).  
Uncertainty in the analysis was addressed by estimating confidence intervals and a cost-effectiveness 
acceptability curve (CEAC), which links the probability of a treatment being cost-effective to a range of 
potential threshold values (λ) that the healthcare system may be willing to pay for an additional unit of effect 
[35]. Commonly, non-parametric bootstrapping can be conducted on the difference in mean costs and mean 
ADRs to generate ICER replicates with which to construct a CEAC [36]. However, the CEAC in this analysis 
was estimated parametrically using the net benefit regression framework following the method proposed by 
Hoch et al. [37]. The CEAC explicitly presents the uncertainty relating to the threshold value coupled with the 
statistical variability inherent in trial data.  
Finally, a series of scenario analyses was performed which varied the time required by all healthcare 
professionals to complete the intervention by +/- 50%. The incremental cost-effectiveness analysis was re-run 
using CAHC and the original trial effectiveness data (see ESM Table S2). The aim was to assess the cost-
effectiveness of this intervention if it was to be  implemented in usual clinical care by hospitals today. Analysis 
was performed using STATA® version 13 and Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, 
USA).  
2.6 Guidelines and Ethical Considerations  
This manuscript followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
guidelines for reporting health economic evaluations [38] (see ESM Table S3) with joint reference to the 
published good research practices for cost-effectiveness analysis alongside clinical trials, i.e. the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research Practices: 
Randomized Clinical Trials-Cost-Effectiveness Analysis (ISPOR RCT-CEA)  report [39]. The original clinical 
cluster randomised trial conformed to Consolidated Standards of Reporting Trials (CONSORT) guidelines [40]. 
The research ethics committee (institutional review board) of the local teaching hospitals network approved the 
trial protocol and the trial was registered with the United States National Institutes of Health (NCT01467050- 
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http://clinicaltrials.gov/show/NCT01467050). Written consent was sought and obtained from all participating 
patients, prior to enrolment in the original cluster RCT study.  
3 Results  
The physician-led STOPP/START intervention resulted in a marked absolute risk and relative risk reduction for 
incident ADRs i.e. 11.4% and 47.7% respectively [19]. However, this was accompanied by an increased cost 
relative to usual medical and pharmaceutical care (see Table 3). The mean (standard deviation (SD)) cost of 
caring for an intervention patient during a single admission was €12,102 (€13,490). In the control group, the 
mean (SD) cost of care was €11,160 (€12,506). Median costs were higher for the intervention group (€7,430) 
compared to the control group (€7,380). Following application of a multi-level mixed effects model in 
STATA® version 13 and accounting for baseline differences across both arms, the adjusted incremental 
difference in cost of €877 was statistically non-significant.   
In contrast, the effectiveness measures favoured the intervention strategy and were statistically significant. The 
odds ratio for a patient experiencing an ADR was 0.391 when comparing the intervention (STOPP/START) 
group to the control (usual hospital care) group. This related to an adjusted difference in the mean number of 
ADRs of −0.164. Although the physician-implemented STOPP/START intervention was more costly, it too was 
more effective than usual clinical care. The calculated ICER was €5,358 for the prevention of an ADR.  
However, as with all attempts to calculate the cost-effectiveness of an intervention, there is a degree of 
uncertainty surrounding the ICER. Even if the healthcare payer was willing to pay the €5,358 for the prevention 
of an ADR, the probability of the intervention being cost-effective was 50%. There was a 92.6% probability that 
the intervention would be cost-effective if the healthcare payer was willing to pay €20,000 for the prevention of 
an ADR (see Table 3). When the cost-effectiveness analysis was rerun using CAHC and the original trial 
effectiveness data, the ICER underwent a slight increase to €5,469 (see ESM Table S2). Scenario analyses 
demonstrated that if healthcare professional times associated with the intervention were altered by +/- 50%, this 
had a minimal effect on the original ICER estimate (see ESM Table S4). This was also true of the scenario 
analyses that used CAHC and original trial effectiveness data (see ESM Table S5). 
The overall cost of applying the STOPP/START intervention to a group of 360 patients was estimated to be 
approximately €18,000 or €50 per patient. The majority of the intervention costs were associated with the 
expense of the research physician’s time conducting the intervention (~€33 per patient). Length of hospital stay 


















Table 3 Incremental cost-effectiveness analysis using 2012 data 
  Intervention group (n = 360)  Control group (n = 372)  
Cost analysis   
Total healthcare cost (€)      
    Mean (SD)  12,102 (13,490)  11,160 (12,506)  
Effectiveness analysis   
Participants experiencing ≥ 1 
ADRs [n (%)]  
42 (11.67)  78 (20.97)  
ADRs experienced per patient 
[n (%)]  
    
    0  318 (88.33)  294 (79.03)  
    1  39 (10.83)  67 (18.01)  
    2  3 (0.83)  11 (2.96)  
ADRs per patient [mean  
(SD)]  




Intervention vs Control  
Incremental cost  
Difference in mean healthcare 
cost (€) (a,b) 
877 (95% CI −1807, 3561) 
Incremental effect  
Difference in odds ratio for 
ADR events (a,c) 
0.391 (95% CI 0.233, 0.657)  
Difference in mean ADR events 
(a,c)    
−0.164 (95% CI −0.257, −0.070)  
ICER per ADR averted (€) 5,358 
Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
             0  0.236 
         500  0.255 
      1,000  0.275  
      5,000  0.455 
    10,000  0.680 
    20,000  0.926 




a) Reported estimates for incremental differences in costs and effects adjusted to account for baseline 
differences between arms  
b) Regression for total costs estimated using multilevel mixed-effects linear regression models and 
controlling for treatment arm, age, sex, number of medications at admission and clustering 
c) Regression for ADR event estimated using mixed effect logistic regression models and controlling for 
treatment arm, age, sex, number of medications at admission and clustering 
d) Probabilities for cost-effectiveness estimated parametrically using net benefit regression models for 
analysis at each threshold value 
4 Discussion  
It is unlikely that the physician-led STOPP/START intervention is cost-effective. For instance, at a willingness-
to-pay threshold of €10,000 per ADR averted; the probability of the intervention being cost-effective is only 
68%. The probability of the intervention being cost-effective increases to 92.6% if a significantly higher 
threshold of €20,000 is applied. The willingness-to-pay thresholds used in this analysis were arbitrary but when 
one considers that the mean cost associated with a single ADR event in secondary care has been estimated at 
€2,250 [41], the threshold values presented in Table 3 are a reasonable measure of what could be considered 
value for money. This cited mean cost of a single ADR also suggests that it is unlikely decision-makers would 
be willing to pay the quoted threshold values because a high probability of cost-effectiveness is only reached at 
high threshold values.. Similar increases in the cost of care could be imputed from this study, as patients who 
experienced an ADR had their median LOS increased by three days [19].  
The principal barrier to the application of this intervention by a trained physician at a wider level is physician 
working hours’ capacity. The senior resident research physician screened no more than four new patients each 
day for trial enrolment during the cluster RCT. It should be noted that the research physician was not employed 
on a full-time basis to apply the intervention to patients. If all older hospitalised patients were to receive this 
level of pharmaceutical care, increased staff numbers would likely be required. However, given the results from 
the analysis, it could be argued that the role of the specialist physician is to conduct all relevant medical duties 
in the secondary care environment. Although there are some published data in the primary care setting literature 
[42], we could find no reputable references dealing with economic analyses of physician-led medication-related 
interventions in the secondary care setting literature. Thus, it is difficult to align the results of this analysis with 
similar studies. One similar trial involving a research pharmacist conducting a similar medication review-based 
intervention supported by computerised CDSS proved to be cost-effective relative to routine hospital care [23]. 
A recent systematic review investigating the effectiveness and cost-effectiveness of interventions aimed at 
preventing medication error (medicines reconciliation) at hospital admission demonstrated that the majority of 
these interventions are pharmacist-led, not physician-led [43] and that the pharmacist-led interventions are 
generally considered more cost-effective than the respective study comparator [44]. In addition, two ongoing 
European multi-centre randomised clinical trials i.e. SENATOR and OPERAM [45, 46] implement the 
STOPP/START criteria using a computerised CDSS. A recent systematic review concluded that computerised 
interventions are associated with a significant reduction in potentially inappropriate prescribing (PIP) in older 
hospitalised patients [47]. Computerised interventions in this field appear to reduce cost [48] and be cost-
effective [49]. It is also envisaged that the application of STOPP/START criteria in the SENATOR and 
OPERAM trials may prove less labour-intensive and more cost-effective than its application in the trial analysed 
in this study. Given all of this evidence, it is likely that the more clinically effective and cost-effective 
medication screening interventions in older hospitalised patients in the future will comprise of pharmacist-led 
and/or computerised CDSS interventions. 
A study conducted in Canada assessed the cost-effectiveness of self-managed versus physician-managed oral 
anticoagulant therapy over a 5-year period using a Bayesian Markov model [50]. Self-management resulted in 
fewer adverse drug events than physician management with the average discounted incremental cost of self-
management relative to physician management calculated to be $989 per patient with incremental QALYs of 
0.07 gained [50]. Although this study did not assess medication screening in the elderly per se, it is yet another 
example of where a physician-implemented medication intervention was not found to be cost-effective. 
Conversely, the literature once again appears to favour medication screening programmes involving or 
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implemented by pharmacists. This point is supported by two recently published studies demonstrating cost-
effectiveness of pharmacist-driven medication reviews towards optimisation in older patients [15, 51]. 
Notwithstanding the research physician’s absence during medical rounds, the 83.4% acceptance rate of 
STOPP/START recommendations by attending doctors is noteworthy [19]. However, in a very similar analysis 
where the research pharmacist was absent during medical rounds, a lower acceptance rate of 38.5% by attending 
doctors was notable [52]. As the present analysis argues that pharmacist-led medication screening interventions 
are an effective and a cost-effective solution, the low rate of acceptance of pharmacist prescribing 
recommendations by attending physicians needs to be further investigated. In relation to pharmacist medication 
reviews, a robust method for economic evaluation of such medication assessments has been elucidated [53]. 
Ideally, the evaluation should be conducted with a 1-year follow-up period from a healthcare service provider 
viewpoint. Health-related quality of life (HRQoL) is contended as the preferred effectiveness measure utilised, 
allowing correlation with confirmed societal values. The ultimate and most comprehensive appraisal would be a 
cost-benefit evaluation over a 5-year period from a societal perspective. Thus, if the standard practice model of 
medication reviews is to be pharmacist-led, the economic evaluation aspect of such reviews should be 
conducted using the proposed methods. 
The cluster randomisation of the RCT that this evaluation is based upon resulted in a statistically significant sex 
imbalance between the control and intervention groups (significantly fewer women in the control group (49.7%) 
than in the intervention group (63.9%)). Although sex imbalance in any RCT is not desirable, there is no 
evidence to indicate that sex had a significant influence on the prevalence rates of PIMs, PPOs, or incident 
ADRs in the trial. The literature has shown that females experience higher rates of PIMs and ADRs relative to 
males [54-56]. Given the higher proportion of women in the intervention group, one would have expected 
higher rates of ADRs in this arm yet the results demonstrated the contrary. Therefore, it is unlikely that the sex 
imbalance between groups had a significant influence on primary outcome results. There were no other 
significant demographic differences between the two treatment arms. As stated, demographic analysis is 
presented in the original RCT paper [19]. 
It has been established that conducting economic evaluations based on data from RCTs is a suitable 
methodology [57]. This approach has two main advantages i.e. (i) internal validity is maintained due to the 
comprehensive nature of data collection during the trial and (ii) there is a modest marginal cost associated with 
collecting required data from a trial which is predominantly clinically orientated [57]. While a cost-utility 
analysis with a health-related outcome measure is recommended as the reference case in the Republic of Ireland 
[28], it was not a realistic outcome measure for this analysis. The population under consideration had multiple 
co-morbidities and often an initially poor health status [19]. Therefore, HRQoL was not appropriate in this case 
[58]. Appropriate methods were used to investigate the cost-effectiveness analysis of the trial data. Multi-level 
mixed effect models were chosen as they are an acceptable means for estimating the incremental net benefits for 
a clinical trial of this nature. Clustered data can potentially lead to biased results [59]. Normal statistical 
analyses are generally inappropriate, however the methods employed for our analysis surmounted this issue 




There are several limitations to this economic evaluation, principally pertaining to extrapolation of the findings 
to routine clinical practice. Training costs and time estimates were not recorded at time of event and were 
retrospectively informed by the primary research team. It is likely that some costs associated with this 
intervention may have been overestimated or underestimated. For example, the seven minute time period 
allocated for discussion of STOPP/START recommendations could vary considerably depending on the number 
of recommendations generated and the subjective prescribing assessment thought processes of the attending 
consultant. In addition, the 30-minute time period allocated to compiling the research physician’s printed report 
could be replaced by a five minute handwritten summary of recommendations into patients’ medical records. 
However, the scenario analysis demonstrated that if healthcare professional time associated with intervention 
implementation was altered by 50% in both directions, this had a minimal effect on the original ICER estimate 
(see ESM Table S4). Furthermore, a time and motion study, which gathers data on healthcare professional time 
required to complete the intervention, would have reduced uncertainty surrounding this input. As healthcare 
professionals become more familiar with the application of the STOPP/START criteria, they will be able to 
apply them more effectively and arrive at decisions at a faster rate.  
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ADRs are often compared to icebergs [60]; those that are visible and identified, and those that are below the 
water’s surface where neither patient nor intervening clinician recognise that they are drug effects, and thus 
unquantifiable. Therefore, it is possible that the amount of ADRs identified in both arms of the trial is not the 
true value. Depending on the type and severity of ADR, the cost, patient LOS, and overall impact on healthcare 
utilisation can vary dramatically [41, 61]. This level of detail was not reflected in our evaluation. Therefore, it is 
potentially dangerous to dismiss the intervention as not being cost-effective because the outcome at the time was 
not measureable or identifiable. There are also those that may be causing no symptoms or signs at the time but 
represent a real risk in the future. Ideally, a longer duration of follow-up for ADR evaluation would have been 
more preferable as it possibly could have allowed for further identification of ADRs. 
Moreover, this evaluation is based on the work of one research physician in a single centre. Aspects of the 
intervention that would be variable between sites include the clinical experience of the research physician 
involved and the extent of the uptake of STOPP/START criteria recommendations by the receiving medical 
team. The attending physician is solely responsible for deciding whether the application of the STOPP/START 
criteria is clinically important or not. This is a subjective choice, irrespective of formal training. There are other 
examples of medication optimisation due to the application of the STOPP/START screening tool [22]. This 
single study site increased the possibility of crossover learning between healthcare colleagues within the 
secondary care environment. However, if healthcare decision-makers are insistent about supporting and 
promoting physician-led medication screening interventions,  this evaluation should be carried out on a larger 
scale involving multiple hospital sites as in the SENATOR and OPERAM trials [45, 46]. 
As stated, the trial was conducted in 2011/2012 and cost-effectiveness was calculated using 2012 healthcare 
costs. When the analysis was re-run using CAHC and original trial effectiveness data, the cost of the 
intervention was marginally lower (see ESM Table S1); however, there was a slight ICER increase which is 
attributed to the increased 24-hour national Irish hospital stay average cost per patient (see ESM Table S2). It is 
unlikely that healthcare policy decision-makers would execute the rollout of this intervention today as it has 
become less cost-effective recently. However a budget impact analysis would have to completed alongside the 
cost-effectiveness analysis to assess if policymakers were serious about its adoption [62]. In addition, the results 
of economic analyses based on RCTs must be interpreted with caution especially if there are limitations or flaws 
inherent in trial design. However, the RCT that formed the basis of the present cost-effectiveness analysis 
achieved 80% power to detect a statistically significant difference in ADR incidence between the groups at the 
95% confidence level [19]. It would have been interesting to calculate the incremental net benefit statistic to 
derive the same conclusion on cost-effectiveness like that of the ICER. This was not possible since a 
willingness-to-pay threshold for ADRs has not yet been elucidated. 
This is the first study to evaluate the economic impact of a physician-led medication review intervention based 
upon the STOPP/START criteria. Since their development in 2008 [21], STOPP/ START criteria have become 
an extensively used method of identifying and improving instances of potentially inappropriate prescribing [52, 
63]. This analysis provides further information about the adoption of STOPP/START guidelines as a 
fundamental part of any healthcare review conducted by a healthcare professional in an older population. The 
present analysis has implemented recommendations from the CHEERS statement to ensure that this manuscript 
presents a transparent high quality evaluation.    
5 Conclusion  
Based on the information extracted from the cluster RCT, the physician-implemented medication screening tool 
based on the STOPP/START criteria is unlikely to be considered cost-effective. The healthcare payer would 
have to pay €20,000 to attain a 92.6% probability that this intervention, which prevents ADRs, is cost-effective. 
However, as the authors are unaware of decisions previously made based on the cost per ADR prevented, there 
is uncertainty regarding the cost-effectiveness status of the intervention from a policy perspective. Moreover, 
while the difference in incremental effects on an individual basis did demonstrate statistical significance, the 
difference in overall incremental costs did not. To date, the literature appears to be sparse with regard to 
physician-implemented medication review interventions in secondary care in contrast with the multiplicity of 
studies describing pharmacist-led programs which appear to be clinically effective and budget positive [44]. At 
a minimum, this evaluation further adds to the growing body of evidence that a structured form of medication 
review and reconciliation incorporating STOPP/START criteria is superior to usual clinical practice. The 
present data suggests that a pharmacist with/without CDSS designed for STOPP/START criteria employed to 
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carry out such medication reviews may be a more cost-effective approach than a medication review by a 
specialist physician. 
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Electronic Supplementary Table S1   
 Costs associated with care of patients in intervention arm in 2015 (CAHC) 
Cost Component  Unit 
Cost (€) 




criteria (once off) 
0.56  
 
circa 240 minutes of training 
required costing approximately 
€200.00 
 
Experience-based opinion from 
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minutes (Experience-based opinion 
from original research team) 
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Approximated time of seven 
minutes (Experience-based opinion 
from original research team) 
 









Approximated time of 30 minutes 
(Experience-based opinion from 
original research team) 
 
HSE salary scales [64] 
Hospitalisation 
Costs 
839.00 24-hour national Irish hospital stay 
average cost per patient  
Healthcare Pricing Office [65] 
Key: HSE – Health Service Executive  
Electronic Supplementary Table S2   
Incremental cost-effectiveness analysis using CAHC and original trial effectiveness data 
  Intervention group (n = 360)  Control group (n = 372)  
Cost analysis   
Total cost (€)      
    Mean (SD)  12,380 (13,802)  11,419 (12,795)  
Effectiveness analysis   
Participants experiencing ≥ 1 
ADRs [n (%)]  
42 (11.67)  78 (20.97)  
ADRs experienced per patient 
[n (%)]  
    
    0  318 (88.33)  294 (79.03)  
    1  39 (10.83)  67 (18.01)  
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    2  3 (0.83)  11 (2.96)  
ADRs per patient [mean  
(SD)]  




Intervention vs Control  
Incremental cost  
Difference in mean healthcare 
cost (€) (a,b) 
895 (95% CI −1851, 3642) 
Incremental effect  
 Difference in odds ratio for 
ADR events (a,c) 
0.391 (95% CI 0.233, 0.657)  
Difference in mean ADR events 
(a,c)    
−0.164 (95% CI −0.257, −0.070)  
ICER per ADR averted (€) 5,469 
Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
             0  0.236 
         500  0.255 
      1,000  0.274 
      5,000  0.450 
    10,000  0.672 
    20,000  0.921 
Key: SD = standard deviation; ADR = adverse drug reaction; CI = confidence interval; ICER = incremental 
cost-effectiveness ratio 
a) Reported estimates for incremental differences in costs and effects adjusted to account for baseline 
differences between arms  
b) Regression for total costs estimated using multilevel mixed-effects linear regression models and 
controlling for treatment arm, age, sex, number of medications at admission and clustering 
c) Regression for ADR event estimated using mixed effect logistic regression models and controlling for 
treatment arm, age, sex, number of medications at admission and clustering 
d) Probabilities for cost-effectiveness estimated parametrically using net benefit regression models for 
analysis at each threshold value 
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subgroups analysed, including why they were chosen. 
Pg 3 
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made. 
Pg 2 
Study perspective 6 Describe the perspective of the study and relate this to the 
costs being evaluated. 
Pg 3 
Comparators 7 Describe the interventions or strategies being compared and 
state why they were chosen. 
Pg 2 
Time horizon 8 State the time horizon(s) over which costs and consequences 
are being evaluated and say why appropriate. 
 Pg 3 
Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
Pg 4 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 





11b Synthesis-based estimates: Describe fully the methods used 
for identification of included studies and synthesis of 







12 If applicable, describe the population and methods used to 









Estimating costs and 
resources 
13b Model-based economic evaluation: Describe approaches and 
data sources used to estimate resource use associated with 
model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to 
opportunity costs. 
Pg 4 
Currency, price date 
and conversion 
14 Report the dates of the estimated resource quantities and unit 
costs. Describe methods for adjusting estimated unit costs to 
the year of reported costs if necessary. Describe methods for 
converting costs into a common currency base and the 
exchange rate. 
Pg 5 
Choice of model 15 Describe and give reasons for the specific type of decision-
analytical model used. Providing a figure to show model 
structure is strongly recommended. 
N/A 
Assumptions 16 Describe all structural or other assumptions underpinning 
the decision-analytical model. 
N/A 
Analytical methods 17 Describe all analytical methods supporting the evaluation. 
This could include methods for dealing with skewed, 
missing, or censored data; extrapolation methods; methods 
for pooling data; approaches to validate or make adjustments 
(such as half cycle corrections) to a model; and methods for 
handling population heterogeneity and uncertainty. 
Pg 6 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report reasons 
or sources for distributions used to represent uncertainty 
where appropriate. Providing a table to show the input 
values is strongly recommended. 
N/A 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as 
well as mean differences between the comparator groups. If 




20b Model-based economic evaluation: Describe the effects on 
the results of uncertainty for all input parameters, and 





21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between 
subgroups of patients with different baseline characteristics 
or other observed variability in effects that are not reducible 














22 Summarise key study findings and describe how they 
support the conclusions reached. Discuss limitations and the 




Source of funding 23 Describe how the study was funded and the role of the 
funder in the identification, design, conduct, and reporting of 
the analysis. Describe other non-monetary sources of 
support. 
Pg 12 
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors comply 




Electronic Supplementary Table S4  
Scenario analysis using 2012 data 
50% increase in healthcare professional time  Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean  
  900 (95% CI −1783, 3584) 
  
Incremental Effect: No. of ADR Events (n)     
Difference in Mean  
 −0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,500 
50% decrease in healthcare professional time Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean 
854 (95% CI −1831, 3539) 
Incremental Effect: No. of ADR Events (n)     
Difference in Mean 
−0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,216 
Key: ADR = adverse drug reaction; CI = confidence interval 
 
Electronic Supplementary Table S5  
Scenario analysis using CAHC and original trial effectiveness data  
 50% increase in healthcare professional time Incremental Analysis - Intervention vs Control 
22 
 
Incremental Cost: Total Cost (€) 
Difference in Mean  
 918 (95% CI −1828, 3664) 
  
Incremental Effect: No. of ADR Events (n)      
Difference in Mean  
 −0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,608  
50% decrease in healthcare professional time Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean 
  872 (95% CI −1875, 3620) 
Incremental Effect: No. of ADR Events (n)     
Difference in Mean 
−0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,330 
Key: ADR = adverse drug reaction; CI = confidence interval 
